The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Growth Is Projected For The Generic Pharmaceuticals Contract Manufacturing Market During The Forecast Period 2026–2030?
The generic pharmaceuticals contract manufacturing market has witnessed substantial growth in recent years. Its value is projected to climb from $66.82 billion in 2025 to $71.65 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.2%. This historical expansion can be attributed to several factors, including restricted contract manufacturing alternatives, a reliance on in-house generic drug manufacturing, an escalating demand for off-patent APIs, a surge in generic drug approvals, and financial constraints faced by pharmaceutical companies.
The generic pharmaceuticals contract manufacturing market is projected to experience robust expansion in the coming years. Its size is forecast to reach $93.56 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.9%. This growth during the forecast timeframe is primarily driven by factors such as an increase in worldwide generic drug demand, the enlargement of contract manufacturing organizations (CMOs), the integration of sophisticated formulation technologies, a heightened emphasis on biologics and intricate generics, and enhanced international regulatory cooperation. Key trends anticipated for this period encompass a growing tendency to outsource generic drug production, an emphasis on economically efficient manufacturing and packaging, the broadening of services for injectable and tablet production, enhanced regulatory assistance and adherence services, and an expansion in licensing and technology transfer arrangements for generic items.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25771&type=smp
What Underlying Factors Are Accelerating The Growth Of The Generic Pharmaceuticals Contract Manufacturing Market?
The increasing need for biosimilars is anticipated to fuel the expansion of the generic pharmaceuticals contract manufacturing market in the future. These are biological medical products that bear a strong resemblance to existing approved reference biologics, lacking any significant clinical distinctions in terms of safety, purity, or potency. The primary reason for the growing demand for biosimilars stems from their capability to offer economical substitutes for costly biologic medications, thereby enhancing access to advanced therapies for patients and healthcare providers. Contract manufacturing in generic pharmaceuticals aids biosimilars by offering economical, large-scale production facilities and the necessary regulatory knowledge to expedite their market introduction and guarantee uniform quality. For example, data from Cardinal Health Inc., a US-based healthcare company, indicated that in January 2023, the U.S. had 33 biosimilar products approved by the FDA as of January 2022, with 21 available on the market. By 2023, this figure increased to 40 FDA-approved biosimilars, of which 25 were commercially accessible. Consequently, the expanding need for biosimilars is propelling the growth of the generic pharmaceuticals contract manufacturing market.
What Market Segments Are Evaluated Within The Generic Pharmaceuticals Contract Manufacturing Market?
The generic pharmaceuticals contract manufacturing market covered in this report is segmented –
1) By Drug Type: Branded Generics, Unbranded Generics
2) By Product Type: Pharmaceutical Active Pharmaceutical Ingredients, Formulations, Capsules, Tablets, Injectables
3) By Route Of Administration: Oral, Parenteral, Topical, Other Routes Of Administration
4) By Application: Oncology, Immunology, Antidiabetic, Neurology, Anticoagulants, Cardiovascular, Respiratory, Pain, Human Immunodeficiency Virus Antivirals
5) By End-User Industry: Pharmaceutical Companies, Contract Research Organizations, Biotechnology Companies, Generic Drug Manufacturers
Subsegments:
1) By Branded Generics: Contract Development of Branded Formulations, Branded Generic Tablet Manufacturing, Branded Injectable Manufacturing, Packaging and Labeling for Branded Generics, Regulatory Support For Branded Generics
2) By Unbranded Generics: Bulk Manufacturing of Off-Patent Active Pharmaceutical Ingredients, Generic Tablet Or Capsule Production, Parenteral Or Injectable Generic Manufacturing, Cost-Efficient Packaging for Unbranded Products, Licensing And Tech Transfer for Generic Products
What Industry Trends Are Redefining The Generic Pharmaceuticals Contract Manufacturing Market?
Major companies engaged in the generic pharmaceutical contract manufacturing market are expanding their service portfolios by establishing specialized subsidiaries, addressing the rising demand for outsourced development and manufacturing. This strategic initiative to create dedicated subsidiaries enables organizations to streamline the production of active pharmaceutical ingredients (APIs), ensuring compliance, scalability, and operational efficiency throughout the drug development lifecycle. For instance, in July 2025, Lupin, an India-based generic pharmaceutical company, launched its new subsidiary, Lupin Manufacturing Solutions (LMS), to enter the contract development and manufacturing organization (CDMO) market. This specialized division is aimed at supporting the development, manufacturing, and sale of APIs for global pharmaceutical partners. With a leadership team experienced in biotech and pharma, the subsidiary is well-positioned to deliver high-quality contract services, assisting pharmaceutical companies in accelerating their time-to-market while maintaining regulatory standards and cost efficiency.
Who Are The Top Market Participants Influencing The Generic Pharmaceuticals Contract Manufacturing Market?
Major companies operating in the generic pharmaceuticals contract manufacturing market are WuXi AppTec Co. Ltd., Recipharm AB, Siegfried Holding AG, Curia Global Inc., Piramal Pharma Solutions, Laurus Labs Limited., Cambrex Corp., Alcami Corp. Inc, Neuland Laboratories Limited.
Read the full generic pharmaceuticals contract manufacturing market report here:
Which Region Is Projected To Dominate The Generic Pharmaceuticals Contract Manufacturing Market During The Forecast Period?
North America was the largest region in the generic pharmaceuticals contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generic pharmaceuticals contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Generic Pharmaceuticals Contract Manufacturing Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25771&type=smp
Browse Through More Reports Similar to the Global Generic Pharmaceuticals Contract Manufacturing Market 2026, By The Business Research Company
Pharmaceutical Contract Developments And Manufacturing Organization Cmo Market Report 2026
Biopharmaceuticals Contract Manufacturing Market Report 2026
Pharmaceutical Contract Packaging Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model